CARL · Company research
Carlsmed, Inc. Common Stock (CARL): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
20records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Carlsmed Launches aprevo® Lumbar Bi-lateral Posterior System | Carlsmed, Inc. announced the U.S. commercial launch of its aprevo® Lumbar Bi-lateral Posterior System at the North American Spine Society's 41st Annual Meeting. The launch follows a limited market evaluation that began in February 2026. The system leverages the company's AI-enabled software platform to deliver personalized spine fusion solutions, with endorsements from surgeons at University of Colorado and Mayo Clinic. | View source ↗ | GlobeNewswire Inc. | Oct 14, 2026 | bullish | 1 | 1 |
| Carlsmed Launches aprevo® Lumbar Bi-lateral Posterior System | Carlsmed, Inc. announced the U.S. commercial launch of its aprevo® Lumbar Bi-lateral Posterior System at the North American Spine Society's 41st Annual Meeting. The launch follows a limited market evaluation that began in February 2026. The system leverages the company's AI-enabled software platform to deliver personalized spine fusion solutions, with endorsements from surgeons at University of Colorado and Mayo Clinic. | View source ↗ | GlobeNewswire Inc. | Oct 14, 2026 | bullish | 1 | 1 |
| A newly launched system tailors spine-fusion plans and devices to patients - Stock Titan | A newly launched system tailors spine-fusion plans and devices to patients Stock Titan | View source ↗ | Stock Titan | Oct 14, 2026 | neutral | 0 | 0.6 |
| Carlsberg (CPSE:CARL B) Stock Looks Reasonable Following Its UK Brewery Reshuffle - Yahoo Finance | Carlsberg (CPSE:CARL B) Stock Looks Reasonable Following Its UK Brewery Reshuffle Yahoo Finance | View source ↗ | Yahoo Finance | Oct 10, 2026 | neutral | 0 | 0.6 |
| Carlsmed, Inc. (NASDAQ:CARL) Stock Has Consensus Target Price of $19.25 - MarketBeat | Carlsmed, Inc. (NASDAQ:CARL) Stock Has Consensus Target Price of $19.25 MarketBeat | View source ↗ | MarketBeat | Oct 10, 2026 | neutral | 0 | 0.6 |
| Carlsmed (NASDAQ:CARL) Stock: Insider Jeffrey Bertolini Sells 747 Shares - MarketBeat | Carlsmed (NASDAQ:CARL) Stock: Insider Jeffrey Bertolini Sells 747 Shares MarketBeat | View source ↗ | MarketBeat | Oct 6, 2026 | neutral | 0 | 0.6 |
| After exercising options, Carlsmed (CARL)'s COO sells 747 shares at $14.39. - Stock Titan | After exercising options, Carlsmed (CARL)'s COO sells 747 shares at $14.39. Stock Titan | View source ↗ | Stock Titan | Oct 6, 2026 | neutral | 0 | 0.6 |
| Why is Carl Zeiss Meditec stock sliding today? - Investing.com | Why is Carl Zeiss Meditec stock sliding today? Investing.com | View source ↗ | Investing.com | Oct 5, 2026 | neutral | 0 | 0.6 |
| Carlsmed (NASDAQ:CARL) Stock Rating Reaffirmed as "Buy" by BTIG Research - MarketBeat | Carlsmed (NASDAQ:CARL) Stock Rating Reaffirmed as "Buy" by BTIG Research MarketBeat | View source ↗ | MarketBeat | Oct 2, 2026 | neutral | 0 | 0.6 |
| A leader who built Intuitive Surgical's global AI organization now leads Carlsmed's AI and product work. - Stock Titan | A leader who built Intuitive Surgical's global AI organization now leads Carlsmed's AI and product work. Stock Titan | View source ↗ | Stock Titan | Oct 1, 2026 | neutral | 0 | 0.6 |
| Carlsmed (CARL) legal chief holds options on 90,000 shares alongside 56,222 common shares. - Stock Titan | Carlsmed (CARL) legal chief holds options on 90,000 shares alongside 56,222 common shares. Stock Titan | View source ↗ | Stock Titan | Sep 30, 2026 | neutral | 0 | 0.6 |
| Rapid UTI test that returns antibiotic susceptibility in hours gets FDA breakthrough designation - Medical Economics | Rapid UTI test that returns antibiotic susceptibility in hours gets FDA breakthrough designation Medical Economics | View source ↗ | Medical Economics | Sep 21, 2026 | neutral | 0 | 0.6 |
| Carl Icahn Added Nearly 69 Million Shares of His Own Company Last Quarter - 24/7 Wall St. | Carl Icahn Added Nearly 69 Million Shares of His Own Company Last Quarter 24/7 Wall St. | View source ↗ | 24/7 Wall St. | Sep 19, 2026 | neutral | 0 | 0.6 |
| Carlsmed appoints Jeff Bertolini as new COO - The Globe and Mail | Carlsmed appoints Jeff Bertolini as new COO The Globe and Mail | View source ↗ | The Globe and Mail | Sep 9, 2026 | neutral | 0 | 0.6 |
| Carl Icahn just made a troubling move with this embattled stock - TheStreet | Carl Icahn just made a troubling move with this embattled stock TheStreet | View source ↗ | TheStreet | Sep 2, 2026 | neutral | 0 | 0.6 |
| Carl Icahn Dumped His JetBlue Stock At $4.95 A Share - Live and Let's Fly | Carl Icahn Dumped His JetBlue Stock At $4.95 A Share Live and Let's Fly | View source ↗ | Live and Let's Fly | Aug 30, 2026 | neutral | 0 | 0.6 |
| Carl Zeiss Meditec (XTRA:AFX) Stock Margins Cloud A Cheap Looking Valuation - Simply Wall Street | Carl Zeiss Meditec (XTRA:AFX) Stock Margins Cloud A Cheap Looking Valuation Simply Wall Street | View source ↗ | Simply Wall Street | Aug 7, 2026 | neutral | 0 | 0.6 |
| Will Carlsmed, Inc. (CARL) Report Negative Earnings Next Week? What You Should Know - Yahoo Finance | Will Carlsmed, Inc. (CARL) Report Negative Earnings Next Week? What You Should Know Yahoo Finance | View source ↗ | Yahoo Finance | Jul 29, 2026 | neutral | 0 | 0.6 |
| Carlsmed, Inc. (CARL) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance | Carlsmed, Inc. (CARL) Reports Q1 Loss, Tops Revenue Estimates Yahoo Finance | View source ↗ | Yahoo Finance | May 5, 2026 | neutral | 0 | 0.6 |
| Workday stock drops 5%+ after CEO Carl Eschenbach steps down - SiliconANGLE | Workday stock drops 5%+ after CEO Carl Eschenbach steps down SiliconANGLE | View source ↗ | SiliconANGLE | Feb 9, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.